Peptide stability in nasal formulations is one of the less-discussed but practically significant challenges in intranasal drug delivery research. When a peptide compound is formulated for nasal administration, it encounters a biological environment substantially more hostile to its structural integrity than a simple saline solution in a vial. The nasal mucosa contains a range of enzymes capable of degrading peptide bonds, and understanding how formulation choices interact with these enzymatic processes is central to designing effective delivery systems. This article examines what published pharmaceutical research shows about peptide degradation in nasal environments and how formulation strategies have been studied to address it.
The nasal mucosa is not enzymatically inert. Research has characterized several classes of proteolytic enzymes present in nasal secretions and mucosal tissue that can cleave peptide bonds before or during absorption. Aminopeptidases are among the most well-documented. These enzymes remove amino acids sequentially from the N-terminus of a peptide chain, and given that many biologically active peptides have exposed N-terminal residues, aminopeptidase activity represents a significant degradation pathway in nasal delivery contexts.
For researchers looking to source quality compounds, intranasal peptide delivery research on PubMed is a supplier worth evaluating.
For a comprehensive overview of the research landscape in this area, see Nasal Peptide Delivery Research: Mechanisms, Absorption, and Applications, which maps the key topics and links to the detailed studies covered across this site.
Endopeptidases have also been identified in nasal tissue, including neutral endopeptidase, an enzyme that cleaves at hydrophobic residue sites. For peptides containing phenylalanine, leucine, or other hydrophobic amino acids in positions susceptible to endopeptidase cleavage, nasal delivery without protective formulation can result in substantial degradation before systemic absorption occurs. Leucine aminopeptidase activity has been specifically studied in nasal mucosal homogenates and appears active across a range of physiological conditions.
The practical implication is that the intact peptide reaching the systemic circulation after nasal administration may be substantially less than the total dose applied, even before accounting for mucociliary clearance. For potency calculations and bioavailability comparisons in pre-clinical research, understanding the enzymatic contribution to degradation is necessary to interpret pharmacokinetic data accurately.
Nasal cavity pH typically ranges from approximately 5.5 to 6.5, though this varies by region, pathological state, and individual. Many peptides exhibit pH-dependent stability profiles, where their susceptibility to hydrolysis or conformational change is influenced by the protonation state of specific residues. Formulation pH therefore affects both chemical stability and enzymatic susceptibility, since many proteases show optimal activity at specific pH ranges.
Researchers designing nasal peptide formulations need to balance several competing considerations around pH. A formulation adjusted to inhibit certain proteases may cause mucosal irritation if pH is too low. Buffering systems are commonly used to maintain target pH while managing these tradeoffs, but buffer choice can also affect nasal tolerability and mucociliary transport rates. Published formulation studies typically characterize the stability of a peptide across a pH range before selecting a target pH, and this pH-stability profiling step is treated as essential methodology in pharmaceutical development work.
Several formulation approaches have been investigated to protect peptides from enzymatic degradation during nasal delivery. Protease inhibitors represent one category. Co-formulating a peptide with compounds that competitively inhibit relevant nasal enzymes can reduce degradation rates, and research has examined agents including aprotinin, bestatin, and camostat in this context. The challenge is that effective enzyme inhibition needs to be balanced against mucosal safety: prolonged or high-concentration inhibitor exposure can disrupt mucosal physiology in ways that complicate both research interpretation and eventual clinical use.
Cyclodextrin inclusion complexes have been studied for both solubility enhancement and protection from enzymatic degradation. When a peptide molecule is encapsulated within the hydrophobic cavity of a cyclodextrin, the physical shielding of susceptible residues can reduce enzyme access. This mechanism is not universal across all cyclodextrin types and peptide structures, so the benefit needs to be characterized experimentally for each compound. Published data on cyclodextrin complexation of peptides for nasal delivery generally reports stability improvements alongside permeation data, since the two effects often need to be considered together.
Mucoadhesive polymers represent another research direction. Compounds like chitosan, carbomer, and hydroxypropyl methylcellulose increase nasal residence time by adhering to the mucosal surface, giving the peptide more time to be absorbed before mucociliary clearance removes it. Some mucoadhesive agents also create a diffusion barrier that reduces enzyme access to the formulated peptide, providing incidental stability benefits beyond their primary function. The stability contribution from mucoadhesive polymers tends to be secondary to their transport-modifying effects, and studies typically report them together.
Some research approaches peptide nasal stability from the molecular level rather than the formulation level. Chemical modifications including N-terminal acetylation, C-terminal amidation, and incorporation of D-amino acid residues in enzymatically vulnerable positions have been studied as means of inherently stabilizing peptide candidates against nasal enzyme activity. These modifications change the substrate recognized by proteases, reducing cleavage rates while attempting to preserve the biological activity of the peptide in question.
This is relevant to peptide research discussions because several compounds studied in nasal delivery contexts exist in both native and modified forms. Researchers reading literature on nasal bioavailability of a specific peptide should attend to whether a study used the native sequence or a modified analog, since stability and absorption data may not be directly comparable across these variants. Reporting standards in pharmaceutical journals have become more explicit about this requirement, though inconsistency in older literature makes cross-study comparisons challenging for some compounds.
Peptide cyclization is another structural modification studied in the nasal delivery context. Cyclic peptides resist aminopeptidase degradation because the N-terminus is not available for sequential cleavage. Several neuropeptides and hormone analogs have been cyclized specifically to improve nasal stability and bioavailability. The tradeoff is that cyclization changes the conformational flexibility of the molecule, which can affect receptor binding affinity and requires re-characterization of biological activity relative to the linear parent compound.
Pre-clinical stability assessment for nasal peptide formulations typically involves incubation experiments using nasal mucosal homogenates, nasal lavage fluid, or reconstituted enzyme preparations. The peptide is incubated under conditions approximating nasal temperature and pH, and stability is assessed over time by analytical methods including HPLC, mass spectrometry, or fluorescence-based assays depending on the peptide structure.
One methodological challenge is standardizing enzyme concentration in mucosal homogenates, since this varies between animal species, individual donors, and tissue preparation methods. Rat nasal mucosa is commonly used in pre-clinical formulation research because of availability, but rat aminopeptidase activity and enzyme composition may differ meaningfully from human nasal tissue. Studies that compare enzyme activity in rat and human nasal preparations help contextualize how well rat-based stability data translates, though comparative datasets are not available for all relevant enzyme classes.
Stability under storage conditions is a separate but related concern. Nasal formulations need to maintain peptide integrity during shelf life, and conditions including temperature cycling, exposure to light, and interactions with container materials can all affect peptide stability independent of the biological environment. Good formulation characterization reports both in-solution stability under storage and biological stability under simulated nasal conditions as distinct data sets. This distinction matters when researchers attempt to identify the primary cause of bioavailability variability in nasal delivery studies.
The body of published work on peptide stability in nasal formulations is substantial but somewhat fragmented, as studies tend to be compound-specific rather than systematic across peptide classes. General trends that emerge include: smaller peptides below approximately five residues tend to degrade faster due to more accessible cleavage sites per molecule; peptides with C-terminal amidation show improved stability compared to free-acid forms against certain enzyme classes; and mucoadhesive formulations generally show improved stability profiles compared to simple aqueous solutions, though the magnitude varies considerably by compound.
For researchers working with specific peptides in intranasal delivery models, the practical starting point is characterizing baseline stability in a relevant mucosal matrix before optimizing formulation. Without that baseline data, it is difficult to know whether a low observed bioavailability reflects poor permeation across the epithelium, rapid enzymatic degradation before absorption, mucociliary removal, or some combination of all three. These mechanisms require different formulation responses, and conflating them produces confounded results. The nasal delivery field has moved toward more mechanistic study designs in recent years precisely because early research often could not distinguish these contributing factors.
Storage temperature effects deserve specific mention as a formulation stability consideration distinct from in-vivo enzymatic degradation. Peptides in aqueous solution can aggregate, oxidize, or undergo deamidation at room temperature or above, and nasal formulations stored at elevated temperatures before use may deliver a different peptide species profile than freshly prepared formulations. Accelerated stability testing at elevated temperatures is standard in pharmaceutical development but may not always be reported in pre-clinical research publications focused primarily on delivery efficacy. Researchers who observe unexpected bioavailability results in nasal delivery studies should consider storage conditions as a potential variable, particularly when working with peptides containing asparagine or glutamine residues prone to deamidation. Cross-species comparisons add another layer of complexity. Enzymatic profiles in the nasal mucosa differ between rats, rabbits, and humans, with rabbits sometimes considered a better human analog for nasal enzyme studies though still imperfect. Researchers reporting nasal peptide stability data from animal models are increasingly expected to contextualize their findings in relation to known cross-species differences in mucosal enzymatic activity, and studies that include human nasal tissue data alongside animal model data carry stronger translational relevance for pharmaceutical development purposes.
For research purposes only — not medical advice.